Publication | Open Access

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

Ltb4 Receptor AntagonistInflammatory Lung DiseaseAdvanced Lung DiseasePediatricsPediatric Lung DiseaseRandomized Double BlindPulmonary FibrosisPulmonary MedicineMedicinePulmonary Disease